Biologics ineffective for Crohn's, ulcerative colitis, study says

A study published in Gut found that biologic therapies were ineffective in treating inflammatory bowel disease.

Canadian researchers studied how infliximab affected Crohn's disease patients from 1995-2012 and how it affected ulcerative colitis patients from 2000-12.

What they found:

1. When infliximab was introduced to the market, it did not reduce Crohn's disease-related hospitalizations or intestinal resections, nor did it reduce ulcerative colitis-related hospitalizations or colectomies.

2. Infliximab users reported similar findings. However, ulcerative colitis patients' hospitalization rates decreased substantially after infliximab's introduction to the market.

3. In Canada's universal healthcare setting, public payer drug costs increased three times the expected cost for Crohn's disease patients. Researchers said the trend suggested robust market penetration among that group, with no significant outcomes-related changes.

Researchers concluded, "Marketplace introduction of infliximab has not yielded anticipated reductions in the population rates of IBD-related hospitalizations or intestinal resections, despite robust market penetration among patients with CD."

More articles on surgery centers: 
Top, bottom 5 states for CRNA pay
12 physician assistant salary statistics — Average is $106,016
Which states pay physicians the most?

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months